Is the biosimilar dance party mandatory?

The Federal Circuit heard oral arguments this week in Amgen v Sandoz, and the dispute centres on a seemingly simple question that goes to a key part of the Biologics Price Competition and Innovation Act: what does “shall” mean?
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: